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Introduction
The participation of 3,5,3 -tri-iodothyronine (T 3 ) in the regulation of the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis is well established (RodriguezArnao et al. 1993) . T 3 is required for normal GH gene expression and thyroid hormone responsive elements have been identified in the GH gene promoter (Koenig et al. 1987 , DeGroot et al. 1988 , Williams & Brent 1995 . Pituitary GH secretion and GH mRNA level are reduced in hypothyroid rats and restored to normal after treatment with T 3 (Hervas et al. 1975 , Nyborg et al. 1985 . In primary culture of pituitary cells, IGF-I, the major mediator of growth promoting effects of GH, inhibits T 3 induction of GH mRNA and GH release (Melmed & Yamashita 1986 ). In contrast, in the perfused rat liver, physiological doses of T 3 stimulate the synthesis and release of IGF-I (Ikeda et al. 1991) . In hypothyroid rats, serum IGF-I concentration and IGF-I gene expression in liver are reduced (Harakawa et al. 1990) .
The introduction of recombinant GH and IGF-I for the treatment of growth disorders has renewed interest in the study of the effect of GH and IGF-I on thyroid function. The impact of administration of GH to normal and GH-deficient patients on thyroid function has yielded conflicting results. Diverse reports have described a decrease in thyroid uptake of iodine-125, serum thyrotrophin (TSH) and serum thyroxine (T 4 ) and an increase in serum T 3 after administration of GH (Grunfeld et al. 1988 , Jorgensen et al. 1989 , whereas IGF-I administered to Laron-type dwarfs and healthy individuals induces a decrease in TSH and free T 4 , with no change in the T 3 serum concentration (Klinger et al. 1992) .
However, the impact of GH and IGF-I on specific metabolic responses to T 3 in target tissues has received scant attention. In previous studies (Pellizas et al. 1996) , we demonstrated that IGF-I and GH incorporated to cultured rat liver cells induced a time-and dose-dependent reduction in the activity of mitochondrial -glycerophosphate dehydrogenase ( -GPD) and cytosolic malic enzyme (ME), two specific tissue markers of thyroid hormone action (Oppenheimer et al. 1995) . Evidence that the GH effect was mediated by IGF-I was also obtained (Pellizas et al. 1996) .
Although T 3 may exert its effects via different cellular loci, its major effect is the transcriptional regulation of target genes mediated by nuclear thyroid hormone receptors (THR) (Yen & Chin 1994) . The liver represents an important target tissue for thyroid hormone action, with ligand binding studies suggesting abundant expression of high affinity receptors for T 3 (Brent 1994) . The cloning of specific THR complementary DNA (cDNA) led to evidence of the expression of 1 , 2 and 1 THR messenger ribonucleic acids (mRNAs) in rat liver, although concentrations of these mRNAs were low compared with those present in other tissues (Schwartz et al. 1992) . More recently, the development of specific antibodies has provided evidence for abundant expression of 1 , 2 and 1 THR proteins in the rat liver (Chamba et al. 1996) .
Because THR are decisive in the initial steps of thyroid hormone action, we investigated putative modifications at the THR level that could explain the diminished metabolic response to T 3 induced by IGF-I. Results from our previous work provided evidence that the effect of IGF-I could be mediated by a reduction in the number of THRs, as the maximal -GPD and ME activities attained after addition of T 3 to the liver cell culture in a concentration high enough to saturate the THRs fully, were significantly lower in the group pre-exposed to IGF-I (Pellizas et al. 1996) .
In the present study using an in vivo model, we were able to induce a reduction of liver -GPD and ME activities by the administration of IGF-I to normal rats. We also explored the mechanism of IGF-I action on the specific metabolic response to T 3 by measuring the effect of IGF-I on the maximal binding capacity and the affinity constant (K a ) of THR, in addition to the levels of the mRNAs that code for the THR isoforms in the liver. 
Materials and Methods

Materials
Animals and rhIGF-I treatment
Adult male Wistar rats (250 50 g) were given free access to a balanced diet and tap water, and maintained under a 12 h light : 12 h darkness cycle. Rats were injected s.c. with vehicle (0·15 M NaCl) or rhIGF-I every 12 h for different periods of time. Rats were lightly anaesthetized, killed by cervical dislocation, and the liver removed and processed for different purposes. Animal procedures were in compliance with the Guidelines on the Handling and Training of Laboratory Animals published by the Universities Federation for Animal Welfare, and the local Institutional Animal Care Committee.
The doses of rhIGF-I (60-480 µg/100 g BW every 12 h) were selected on the basis of previous reports indicating that a dose of 320 µg/100 g BW per day was able to induce IGF-I-dependent effects .
Isolation of mitochondrial, cytosolic and nuclear fractions
The procedure was similar to that described previously, with slight modifications (Bernal et al. 1978a) . In brief, liver tissue (1 g) homogenized in 0·32 M sucrose-1 mM MgCl 2 with a Teflon-glass motor-driven tissue grinder was centrifuged at 700 g to obtain the crude nuclear pellet. The supernatant was centrifuged at 8500 g for 10 min for the preparation of the mitochondrial fraction. The 8500 g pellet was washed once with 0·125 M potassium phosphate buffer (KBP), pH 7·5. The pellet containing the mitochondrial fraction was resuspended in 3 ml KBP. The initial 8500 g supernatant was centrifuged at 105 000 g to obtain the cytosolic fraction.
The crude nuclear pellet was resuspended in 2·3 M sucrose-1 mM MgCl 2 -2 mM dithiothreitol (DTT)-0·1 mM phenylmethylsulphonyl fluoride and centrifuged at 114 000 g for 30 min in a Beckman 50·1 SW rotor. The pellet was resuspended in 0·32 M sucrose-1 mM MgCl 2 -1 mM CaCl 2--20 mM Tris-2 mM DTT, pH 7·85 (SMCT) and 0·5% Triton X-100. After 1 min at 0 C, the tube was centrifuged at 250 g for 3 min. The pellet was washed once with SMCT. The final pellet containing the purified nuclear fraction was resuspended in 10 ml 0·32 M sucrose-1 mM MgCl 2 -20 mM Tris, pH 7·85 (SMT).
Enzyme activity assays
-Glycerophosphate dehydrogenase [EC 1·1·99·5; sn-glycerol-3-phosphate: (acceptor) oxidoreductase] was assayed in the mitochondrial fraction by the method of Lee & Lardy (1965) and expressed as A/min per mg DNA. Malic enzyme [EC 1·1.1·40; -malate-NADP + oxidoreductase (decarboxylating)] was assayed in the cytosolic fraction by the method of Hsu & Lardy (1969) and expressed as U/mg DNA. One unit (U) was defined as the amount of the enzyme needed to catalyse the reduction of 1 nmol NADP/min using an extinction coefficient for NADPH of E mmol/l 340 =6·3 (Mariash et al. 1980) . The DNA content was evaluated in the total cellular homogenate and in the purified nuclear fraction by the method of Burton (1956) .
[ 125 I]T 3 -binding studies
The maximal binding capacity and the K a of THR were measured in isolated nuclei as described previously (Bernal et al. 1978b) . Briefly, nuclei (200-300 µg DNA/tube) were incubated in SMT with 7·8 10 11 -2·5 10 9 M [ 125 I]T 3 (2200 Ci/mmol). To assess non-specific binding, tubes containing 2·9 10 7 M T 3 were run in parallel. After 2 h incubation at 20 2 C, the nuclei were ice-cooled and centrifuged at 1000 g for 10 min. The nuclear pellets were washed twice in SMCT plus 0·5% Triton X-100 and the radioactivity in the pellet measured. The amount of receptors released to the medium during the incubation period (Bernal & DeGroot 1977) was measured in the 1000 g supernatants by the resin test. Total T 3 binding was calculated by Scatchard analysis (Scatchard 1949 ) from the [ 125 I]T 3 bound to the nuclear pellet and to the supernatants (resin test).
Total RNA extraction
Total RNA was prepared by the one-step acidguanidinium method described by Chomczynski & Sacchi (1987) . In brief, 0·5 g liver was homogenized in 5 ml denaturing solution (4 M guanidinium isothiocyanate, 25 mM sodium citrate pH 7·0, 0·5% N-lauroyl sarcosine and 0·1% -mercaptoethanol). After phenol-chloroformisoamyl alcohol (50 : 49 : 1) extraction, RNA was precipitated in isopropanol, recovered by centrifugation and washed in 75% ethanol. After a further extraction, precipitation and wash, the RNA was dissolved in diethyl pyrocarbonate-treated water and quantified and checked for purity by spectrophotometry at 260 and 280 nm.
Northern blot
Forty micrograms total RNA were electrophoresed in 1% agarose gel containing 0·66 M formaldehyde (Fourney et al. 1988) . This agarose concentration allowed a good separation of the three THR mRNA species: 1 , 6·0 kb; 1 , 5·0 kb; 2 , 2·6 kb (Strait et al. 1990 ). The gel was stained with ethidium bromide to visualize ribosomal RNA (rRNA). After electrophoresis, RNAs were transferred to a nylon membrane.
The membranes were incubated in prehybridization solution containing 30% deionized formamide-5 Denhart's solution (0·1% Ficoll type 400-0·1% albumin-0·1% polyvinylpirrolidone (PVP))-5 SSPE (0·75 M NaCl-0·05 M NaH 2 PO 4 -5 mM EDTA)-1% SDS-200 µg/ml DNA from herring testes, for 5 h at 42 C in hybridization bags. Hybridizations with the probe were performed for 48 h at the same temperature. The entire pBSK + 1 THR cDNA (Koenig et al. 1988) linearized with EcoRI was used as hybridization probe for Northern blots. The entire cDNA is approximately 1·4 kb, and includes the full coding sequence. As the DNA and ligand binding domain are very similar in THR and THR , this cDNA has been used as a common probe for all THR isoforms (Koenig et al. 1988) . To ensure an even loading, the same blots were hybridized using the entire pBR 322 with an 18S rRNA genomic probe. The probes were labelled by the random primer technique with [ -32 P]deoxy-ATP (3000 Ci/mmol). The specific activity of the labelled probes ranged from 2·6 10 9 -3·9 10 9 d.p.m./µg DNA. After hybridization, blots were washed in 2 SSC (0·3 M NaCl-0·015 M sodium citrate)-1% SDS for 20 min at room temperature, followed by 2 SSC-1% SDS for 20 min at 55 C, 1 SSC-1% SDS for 20 min at 55 C and 0·2 SSC-1% SDS for 20 min at 55 C. The membranes were exposed to Kodak X-Omat film at 70 C with intensifying screens, for 20 days in the case of the THR probe, and for 6 h in the case of the 18S rRNA probe. The bands were quantified densitometrically (Shimadzu Dual-Wavelength Chromato Scanner CS-930) at 500 nm and the levels of THR mRNA expressed as the absorbance of the THR signals normalized with that of the 18S rRNA in the same lane.
Glucose determination
The serum glucose concentration was evaluated in samples collected 12 h after the last rhIGF-I dose (48 h treatment), using a commercial kit (Enzymatic glycaemia, Wiener lab, Rosario, Argentina).
Serum thyroid hormone concentrations
Serum concentration of total T 4 (TT 4 ), free T 4 (FT 4 ) and total T 3 (TT 3 ) were measured in samples collected 12 h after the last rhIGF-I dose (48 h treatment) by radioimmunoassay using commercial kits (Diagnostic Products Corporation, Los Angeles, CA, USA). Each sample was assayed in duplicate. Intra-and interassay coefficients of variation were 3·3% and 8·1% for TT 4 , 5% and 8% for FT 4 , and 6·1% and 9·5% for TT 3 .
Statistical analysis
Analysis of multiple intergroup differences in each experiment was conducted by one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. Comparisons between two groups were made using the Student's t-test. P<0·05 was considered statistically significant. Figure 1 shows the effect of increasing doses of rhIGF-I, administered to rats during 48 h, on the activity of -GPD and ME. A reduction in ME activity was observed after 120 µg/100 g BW rhIGF-I (P<0·05). A similar effect on -GPD activity was obtained by the administration of 240 µg/100 g BW (P<0·01).
Results
-GPD and ME activities
Serum glucose concentration
Recombinant human IGF-I treatment every 12 h for 48 h did not induce significant changes in basal serum glucose concentration 12 h after the last IGF-I injection (mean .. values (mM): control 6·78 1·56; rhIGF-I (240 µg/100 g BW) 6·72 0·61; rhIGF-I (480 µg/100 g BW) 7·17 0·72; n=6 in each group, Student's t-test).
Serum thyroid hormone concentrations
The changes in circulating iodothyronines after rhIGF-I administration every 12 h for 48 h are shown in Table 1 . TT 4 concentrations tended to decrease with rhIGF-I treatment, but this failed to reach statistical significance (P=0·09). In contrast, rhIGF-I treatment induced a reduction in FT 4 to 70% of the control value (P<0·02), whereas there was a 22% increase in TT 3 compared with the control value (P<0·03).
[ 125 I]T 3 binding
The effect of rhIGF-I on the THR is shown in Fig. 2 and Table 2 . The administration of rhIGF-I (240 µg/100 g BW) every 12 h for 48 h induced a significant reduction in the maximal binding capacity of THR (37% of control), whereas no significant changes were detected in the K a .
As previously reported (Bernal et al. 1978b) , in both groups (control and rhIGF-I treated), the K a of THR was greater in the supernatant from the 'resin test' than in the nuclear pellet (supernatant/nuclear pellet ratio, control: 1·4, rhIGF-I treated: 1·6). However the maximal binding capacity of THR was greater in the nuclear pellet than in the supernatant (nuclear pellet/supernatant ratio, control: 1·4, rhIGF-I treated: 1·5).
The shape of the Scatchard plot from the control group did not indicate the presence of two different sets of sites for T 3 binding (high and low affinity), as the Hill coefficient (De Lean & Rodbard 1979) was 1·4 for this group.
THR mRNAs
The levels of liver THR mRNA isoforms ( 1 , 1 and 2 ) after administration of rhIGF-I (120-480 µg/100 g BW for 48 h) are shown in Fig. 3 . A significant reduction in 1 , 1 and 2 THR mRNAs was observed after the injection of 120 µg/100 g BW rhIGF-I. THR mRNAs were at the lowest level of detection after 240 and 480 µg/100 g BW rhIGF-I.
Figure 1
Effect of rhIGF-I administration to rats on liver -GPD and ME activities. rhIGF-I was administered s.c. every 12 h for 48 h. Results are expressed as means S.E.M. Eight samples were analysed from each individual animal in each group, in two separate experiments; each analysis was performed at least in duplicate. *P<0·05, **P<0·01 compared with the control group by one-way ANOVA followed by Student-Newman-Keuls test. 
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Results of time-course studies of the effect of rhIGF-I (240 µg/100 g BW) on THR mRNAs are indicated in Fig. 4 . A significant reduction in 1 , 1 and 2 THR mRNAs concentrations was registered after 12 h of rhIGF-I treatment and the values were at the lowest level of detection after 24 h.
The difference between the absorbance ratio for 1 THR mRNA from control animals in Fig. 3 (zero dose of rhIGF-I) and Fig. 4 (zero time) is not of significance, because a wide range of 1 THR mRNA/ 1 THR mRNA ratios has been reported previously (Strait et al. 1990) .
Discussion
The present study demonstrated that the administration of rhIGF-I to normal rats resulted in a diminished metabolic response to T 3 in the liver, evaluated as the activity of -GPD and ME, two T 3 -responsive enzymes (Oppenheimer et al. 1995) . This finding is in accordance with our previous results obtained in an in vitro system of cultured rat liver cells (Pellizas et al. 1996) .
The doses of rhIGF-I that we used in this study were substantially greater than the sustitutive doses used in growth disorders in children (Klinger et al. 1992) . However, serum IGF-I concentration in adult normal rats is about eightfold greater than that in human beings (Yamamoto et al. 1991 , Nanto-Salonen et al. 1993 . Moreover, the lack of effect of IGF-I on the animals' behaviour or on glucose concentrations, suggests that the doses administered to rats may be considered to be in a physiological rather than a pharmacological range ( Jones & Clemmons 1995) .
The mechanism by which IGF-I reduced -GPD and ME activities seems to be mediated by the type I IGF receptor. Although a lack of functional type I IGF receptors has been reported in rat hepatocytes (Massague & Czech 1982 , Jaeggi-Groisman et al. 1990 ), other authors have reported their presence in male (Gruppuso et al. 1991) and female (Venkatesan & Davidson 1990 ) adult rat liver. Moreover, mRNA coding for IGF-I receptors has been reported recently (Lemmey et al. 1997) . Other IGF-I-mediated effects have also been reported in the rat liver (Gosteli-Peter et al. 1994 , Raper et al. 1995 . In contrast, a possible crossreaction of infused IGF-I with the structurally similar liver insulin receptor would be expected to enhance, rather than suppress, the activity of -GPD and ME (Wilson & McMurray 1981) . In addition, although IGF-I is able to reduce insulin serum concentrations (Kolaczynski & Caro 1994) , it seems not to be an explanation for the diminished liver T 3 response, as this effect was also observed in rat liver cells cultured in a medium containing a fixed concentration of insulin (Pellizas et al. 1996) . The involvement of IGF-II/ mannose-6-phosphate receptors in the effect of IGF-I is highly unlikely, as the affinity of these receptors for IGF-I is very low ( Jones & Clemmons 1995) .
The changes in serum thyroid hormone concentrations induced by IGF-I administration are in accordance with previous results obtained after administration of GH to normal and GH-deficient human beings (Grunfeld et al. 1988 , Jorgensen et al. 1994 . The reduction in FT 4 concentrations with a concomitant increase in TT 3 induced by IGF-I treatment, suggests an enhanced conversion of T 4 to T 3 . However, short-term administration of IGF-I to normal adults and Laron-type dwarfs resulted in a reduction in FT 4 but failed to augment TT 3 concentrations (Klinger et al. 1992) . Nevertheless, the changes in serum thyroid hormone concentrations induced by IGF-I Table 2 . could not explain the inhibitory effect on the enzyme activities, because this effect was also seen in vitro in rat liver cells cultured with a fixed concentration of T 3 (1·0 nM) (Pellizas et al. 1996) . Moreover, when cells were incubated with 1 µM T 3 , a concentration large enough to saturate THRs fully (Mariash & Oppenheimer 1983) , the failure to reach the maximal -GPD and ME activities in the group pre-exposed to IGF-I (Pellizas et al. 1996) suggested that the effect of IGF-I might not be related to alterations in nuclear occupancy by T 3 . Instead, such a response could involve a diminished number of functionally active nuclear T 3 binding sites (Sato & Robins 1981 , Pellizas et al. 1996 . The magnitude of the cellular response to thyroid hormone depends on the abundance of nuclear receptors for T 3 . It is therefore possible that physiologically or pharmacologically induced alterations in receptor numbers may be able to modify the tissue response to T 3 (Hodin et al. 1990) . Previous reports indicate that, under several experimental conditions (DeGroot et al. 1977 , Dillmann et al. 1978 , Dillmann & Oppenheimer 1979 , Recúpero et al. 1983 , Kaji & Hinkle 1987 , modifications in the number of THRs paralleled changes in the tissue response to thyroid hormone. Consequently, the diminished number of THRs induced by IGF-I treatment would explain, at least in part, the reduction in the metabolic response to T 3 . However, in spite of the lack of known direct effects of IGF-I on -GPD or ME, this possibility cannot be ruled out.
Although the amount of a specific protein cannot always be predicted on the basis of its mRNA level (Oppenheimer et al. 1995) , the reduction in the concentrations of THR mRNAs after the administration of rhIGF-I (240 µg/100 g BW for 12 h) may account for the reduction in the expression of THR proteins. Regarding the failure to detect THR mRNAs after the administration of 240 and 480 µg rhIGF-I/100 g BW for 48 h, and 240 µg/100 g BW for 24 h, it may be that the use of intermediate doses and times of exposure would produce progressive detectable reductions in THR mRNAs. The diminished amounts of liver mRNA coding for the 1 , 1 and 2 THRs suggest that the mechanism of IGF-I action could involve either a reduction in the rate of transcription of genes coding for the THR isoforms, or an increase in the rate of disappearance of the THR mRNAs. Moreover, an effect of IGF-I that is mediated by a reduction in stimulatory transcriptional factors or by enhanced inhibitory transcriptional factors of THR-coding genes should also be considered.
The possibility that the mechanism of action of IGF-I involves an increase in the 2 THR mRNA coding for a THR protein that lacks the ability to bind T 3 and is known to inhibit the active THRs (Koenig et al. 1989 ) was disregarded, as 2 THR mRNA was concomitantly reduced.
The present results indicate that, in the rat liver, IGF-I modulates thyroid hormone action by a mechanism that involves, at least in part, an effect at the level of THR expression. Therefore, it is possible that IGF-I feeds back to limit the stimulatory action of T 3 on IGF-I synthesis in liver cells (Ikeda et al. 1991) , through THR downregulation.
Even though these effects of IGF-I were observed in experimental animals, our findings may have relevance to a possible impact on thyroid function in patients receiving GH or IGF-I treatment.
